Mathias R, von der Weid P-Y. Involvement of the NO-cGMP-K ATP channel pathway in the mesenteric lymphatic pump dysfunction observed in the guinea pig model of TNBS-induced ileitis. Am J Physiol Gastrointest Liver Physiol 304: G623-G634, 2013. First published December 28, 2012 doi:10.1152/ajpgi.00392.2012.-Mesenteric lymphatic vessels actively transport lymph, immune cells, fat, and other macromolecules from the intestine via a rhythmical contraction-relaxation process called lymphatic pumping. We have previously demonstrated that mesenteric lymphatic pumping was compromised in the guinea pig model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced ileitis, corroborating clinical and experimental observations of a dilated and/or obstructed phenotype of these vessels in inflammatory bowel disease. Many mediators released during the inflammatory process have been shown to alter lymphatic contractile activity. Among them, nitric oxide (NO), an inflammatory mediator abundantly released during intestinal inflammation, decreases the frequency of lymphatic contractions through activation of ATPsensitive potassium (K ATP) channels. The objective of this study was to investigate the role of NO and K ATP channels in the lymphatic dysfunction observed in the guinea pig model of TNBS-induced ileitis. Using quantitative real-time PCR, we demonstrated that expression of Kir6.1, SUR2B, and inducible NO synthase (iNOS) mRNAs was significantly upregulated in TNBS-treated animals. Pharmacological studies performed on isolated, luminally perfused mesenteric lymphatic vessels showed that the K ATP channels blocker glibenclamide, the selective iNOS inhibitor 1400W, and the guanylyl cyclase inhibitor ODQ (1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one) significantly improved lymphatic pumping in quiescent lymphatic vessels from TNBS-treated animals. Membrane potential measurement with intracellular microelectrodes revealed that vessels from TNBS-treated animals were hyperpolarized compared with their sham counterpart and that the hyperpolarization was significantly attenuated in the presence of glibenclamide and ODQ. Our findings suggest that NO and K ATP play a major role in the lymphatic contractile dysfunction that occurred as a consequence of the intestinal inflammation caused by TNBS.
intestine, the lymphatic vasculature begins with lacteals, blind-ended tubes lined with endothelial cells in the center of the villi; it progresses to submucosal and muscular initial lymphatics of the same structure and finally to collecting lymphatics, beginning at the intestinal-mesenteric border (36) . Thanks to layers of lymphatic muscle, mesenteric collectors exert a powerful rhythmical contractile activity able to propel their contents through draining lymph nodes and postnodal lymphatics back into the blood stream (54, 64) . During inflammation, the lymphatic system is critical in transporting dendritic cells, macrophages, and lymphocytes from inflamed sites to lymph nodes, as well as resolving the associated edema (57) . It has been noted that the increased interstitial fluid causes an increase in lymphatic contractility and lymph flow and that the various inflammatory mediators present during an inflammatory episode can cause alterations in lymphatic function (3, 45, 56) .
ATP-sensitive potassium (K ATP ) channels have been shown to control membrane potential of vascular smooth muscle, but also lymphatic muscle (10, 52) . Opening of the channel leads to membrane hyperpolarization, thereby decreasing voltagedependent Ca 2ϩ channel activity and inhibiting smooth muscle contraction (13, 27, 40, 43) . Although several tissue-dependent isoforms exist, the Kir6.1/SUR2B isoform predominates in vascular smooth muscle, with a four and four subunit stoichiometry (7) . The channel activity is heavily modulated by protein kinases (5, 6, 11, 24, 26, 42, 44, 46, 48, 52, 59, 61) . Upregulation of the channel subunits has been shown to occur in disease states such as sepsis (7) and colitis (28) , where inflammation is involved. These situations are often accompanied by an increase in nitric oxide (NO) production. Importantly, NO potently inhibits lymphatic pumping (38, 41, 52, 55) with a concomitant lymphatic muscle hyperpolarization (52, 55) . These studies have shown that the hyperpolarizing and dilatory effects of NO can be reversed by administration of the K ATP channel antagonist glibenclamide (52) . Synthetic agonists that directly act on the K ATP channel subunits such as cromakalim and pinacidil have been shown to cause a hyperpolarization of lymphatic muscle and an inhibition of lymphatic pumping (30, 39, 52) .
Following an earlier study demonstrating inhibition of lymphatic pumping in mesenteric vessels from 2,4,6-trinitrobenzenesulfonic acid (TNBS)-treated guinea pigs, an animal model of intestinal inflammation (60) , we assessed the causes of the dysfunction and the role played by NO and K ATP channels.
METHODS
Ethical approval. The animal handling and experiments were approved by the University of Calgary Animal Care and Ethics Committee and conformed to the guidelines established by the Canadian Council on Animal Care.
Surgical induction of inflammation. Male Hartley albino guinea pigs (Charles River, Montreal, Canada) between 7-15 days of age were housed at constant temperature (22°C) on a 12:12-h light-dark cycle, with food and water ad libitum. Animals were fasted 4 h and anesthetized with isoflurane (induction 4%, maintenance 2.5-3% in oxygen) before a midline laparotomy was performed. The small intestine was exteriorized and placed on a piece of damp gauze soaked in saline and TNBS (Sigma-Aldrich; 0.425 ml, 30 mg/ml in 30% ethanol in 0.9% NaCl) was injected into the lumen of the ileum, 8 -10 cm proximal to the ileocecal junction. An equal volume of saline was injected into the ileum lumen of the sham group to control for volume effects and surgical procedure. The laparotomy was surgically closed and the animals were allowed to recover in the controlled environment of the animal care facility (60) . Animals were euthanized by anesthetic overdose followed by exsanguination either 1 or 3 days after surgery to perform quantitative real-time PCR and in vitro analysis of the lymphatic vessel contractile activity, respectively.
Assessment of inflammation. Inflammation was macroscopically assessed in affected area of the ileum and surrounding tissue immediately after being excised from the euthanized animal according to previously established scoring criteria (60) . Briefly, ileal segments were macroscopically assessed for the level of severity (0, none; 1, moderate; 2, severe) of erythema, hemorrhage, edema, strictures, ulceration, adhesion, and presence of mucus, with a maximum score of 14. Lymphatic vessels from TNBS-treated animals with a damage score below 6 displayed a contractile behavior similar to vessels from control and sham-treated animals (see also Ref. 60) . Lymphatic vessels from animals with a damage score above 10 did not respond to any pharmacological treatments (see Contraction frequency measurements below) and were not considered further. Weight loss was assessed daily as a measure of animal health and used as a reliable indicator of inflammation.
Tissue preparation. Lymphatic vessels were prepared as previously described (9, 16, 58) . Briefly, the small intestine was rapidly dissected and placed in physiological saline solution (PSS) of the following composition (in mM): 2.5 CaCl2; 5 KCl; 2 MgCl2; 120 NaCl; 25 NaHCO 3; 1 NaH2PO4; 11 glucose. The pH was maintained at 7.4 by constant bubbling with 95% O 2-5% CO2. Small mesenteric collecting lymphatic vessels (diameter 180 -230 m) from the ileum region were dissected together with their associated artery and vein and left intact within the surrounding mesentery. The preparations were pinned to a Sylgard-coated organ bath with a volume of 2 ml and used either for mRNA extraction and PCR or for functional assessment of contractile activity and membrane potential. Three experimental animal groups were considered for the assessment of the lymphatic function (contraction frequency measurements and electrophysiology): sham-and TNBS-treated animals and control/untreated animals.
Contraction frequency measurements. The bath containing the lymphatic vessel preparations was mounted on the stage of an inverted microscope and continuously superfused at a flow rate of 3 ml/min with PSS heated to 36°C. The lymphatic vessel lumen was perfused through a fine glass micropipette inserted into an opening cut at the upstream end of the vessel allowing luminal perfusion in the direction of the valves. The flow rate was initially set at 2.5 l/min, a value selected from preliminary experiments in control lymphatic vessels (16, 60) as the most reliable in inducing a regular and consistent rhythmical contraction rate for the duration of the experiment (typically 1-3 h). The preparation was allowed a 30-min equilibration period and the average number of beats per minute over a 5-min period was measured to serve as the baseline control activity. In control and sham-treated animals, only vessels with a consistent pumping frequency of at least 6 contractions/min during the initial 30-min equilibration period were considered. Vessels from TNBStreated animals with a damage score of 6 and higher did not show any contractile activity at this flow rate. To compare contractile behavior between vessels isolated from sham-and TNBS-treated animals, luminal perfusion was gradually increased from 2.5 to 10 l/min, a value shown in previous studies to be the optimal perfusion rate at which pharmacological treatment could resume pumping in quiescent lymphatic vessels from TNBS-treated animals (60) . Flow rate was ultimately set at this value for the remaining of the experiment and vessels allowed to equilibrate for another 20-min period before drugs were added to the superfusing solution. Ultimately, glibenclamide (10 M) was administered to the vessels via the superfusate to control for their ability to contract. Vessels not showing pumping restoration during this treatment were considered nonresponsive and data not analyzed. Nonresponsive vessels were typically collected from animals with a damage score above 10. These animals were thus not considered in this study.
Concentration-response curves were obtained by administering increasing concentrations of the compound being tested with a washout period between each application of at least 15 min or the time necessary for the vessel to recover from the previous application. Contractile activity was recorded during a 5-min period (baseline) preceding a 1-min application of the compound and effects on vessel contraction frequency were assessed during the 5 subsequent min. Data were expressed as contractions per minute or as a percentage of the baseline period.
Lymphatic vessel chambers were observed by videomicroscopy, with diameter changes and contraction frequency continuously measured with a video-dimension analyzer (model V94, Living Systems Instrumentation, Burlington, VT). This device is designed to sense the optically denser wall of the vessel, at a chosen scan line seen on the TV monitor, and to follow any change in vessel diameter with a rapid (Ͻ20 ms) time resolution. Data were then recorded on a computer via an analog-to-digital converter (PowerLab/4SP, ADInstruments, Mountain View, CA).
Electrophysiology. Mesenteric preparations were mounted in a small organ bath (volume 100 l), placed on the stage of an inverted microscope and continuously superfused with PSS heated to 36°C at a flow rate of 3 ml/min causing a changeover time of Ͻ7 s, as previously described (9, 16, 58) . Impalements of lymphatic muscle cells were obtained from the adventitial side of a lymphatic vessel by using conventional glass intracellular microelectrodes filled with 0.5 M KCl (resistance 150 -250 M⍀). Electrodes were connected to an amplifier (Intra 767, World Precision Instruments, Sarasota, FL) through an Ag-AgCl half-cell. Resting membrane potential was monitored on a digital oscilloscope (VC6525, Hitachi) and simultaneously recorded on a computer via an analog-digital converter (PowerLab/ 4SP, ADInstruments).
Lymphatic muscle impalements were characterized by a sharp drop in potential that settled after 10 -15 s to a value typically more negative than Ϫ45 mV in vessels from control and sham-treated animals. Antagonists and inhibitors were typically applied through the superfusion, and their effect on membrane potential was monitored for 15-20 min.
Quantitative real-time PCR. Mesenteric lymphatic vessels, arteries, and ileum from control, sham-treated, and TNBS-treated guinea pigs were quickly microdissected out, flushed with PBS to remove luminal contents, cleaned of surrounding tissue, and immediately immersed into RNase-and DNase-free collection tubes containing the RNA stabilization reagent RNAlater (Qiagen, Mississauga, ON, Canada). The RNA-stabilized, microdissected tissue was homogenized and disrupted by using sonication QIAshredder (Qiagen) and underwent RNA extraction with the Qiagen Micro RNeasy kit (Qiagen). Subsequent cDNA synthesis was undertaken using Superscript II Reverse Transcriptase enzyme (Invitrogen) with oligo(dT) primers. Real-time amplification of target genes was performed with QuantiTect SYBR Green (Qiagen) in an iCycler iQ Real-Time PCR Instrument (BioRad). Guinea pig real-time primer sequences for SUR2B, Kir6.1, inducible NO synthase (iNOS), and endothelial NO synthase (eNOS) were designed by using the first-release guinea pig genome sequence published on ensembl (www.ensembl.org) by using Primer 3 software (http://frodo.wi.mit.edu/primer3/). Expression of ␤-actin cDNA was used to normalize expression of the genes under study. Real-time primer sequences, as well as the associated ensembl accession numbers, are listed in Table 1 . cDNA amplification for all genes was performed using an annealing temperature of 55°C and 50 cycles. Real-time PCR results were analyzed by the ⌬⌬CT method. PCR products sequences were verified by the University of Calgary Core DNA service.
Chemicals and drugs. Glibenclamide and indomethacin were purchased from Sigma-Aldrich; ODQ (1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one) from Alexis (San Diego, CA); spermine NONOate and 1400W from Cayman Chemical; and cromakalim from Tocris Cookson (Ellisville, MO). Stock solutions of indomethacin were prepared in 100% ethanol; 1400W, glibenclamide, cromakalim, and ODQ in DMSO; and spermine NONOate in 0.01 NaOH. The compounds were then diluted in PSS to achieve the appropriate concentration. The final concentration of each vehicle was always Յ0.1% (vol/vol), a concentration that had no effect on lymphatic contractile and electrical activities.
Data and statistical analysis. Data are expressed as means Ϯ SE. Concentration-response curves were built and the concentration of the agonist causing half-maximal pumping inhibition (IC 50) was estimated by computerized nonlinear regression analysis (Prism, GraphPad software). Statistical significance was assessed by a two-tailed paired and unpaired Student's t-test and ANOVA with appropriate post hoc tests (as specified in the text), with P Ͻ 0.05 being considered significant.
RESULTS
Nitric oxide inhibits lymphatic pumping and hyperpolarizes the lymphatic muscle in control guinea pigs. We used spermine NONOate to assess the effect of NO on rhythmically contracting lymphatic vessels isolated from control animals. Oneminute applications of 100 and 300 M of the NO donor caused a concentration-dependent decrease in contraction frequency (n ϭ 10, Fig. 1, A and B) . NO-induced pumping inhibition was significantly reduced in the presence of 10 M ODQ, a soluble guanylyl cyclase inhibitor (n ϭ 5, Fig. 1 , C and D). Spermine NONOate also caused a hyperpolarization of the lymphatic muscle membrane potential, which was concentration dependent (n ϭ 3; Fig. 1E ) and inhibited by 10 M ODQ (Fig. 1F) .
Activating K ATP channels inhibits lymphatic pumping and hyperpolarizes lymphatic muscle in control guinea pigs. A 1-min application of the synthetic K ATP channel opener cromakalim resulted in a significant inhibition of pumping in lymphatic vessels from control animals. This effect was concentration dependent with an IC 50 Lymphatic vessels are dysfunctional in TNBS-treated guinea pigs. Surgical instillation of TNBS into the ileum of guinea pigs caused an acute intestinal inflammation as evidenced by increased macroscopic damage scores, compared with shamtreated animals (9 Ϯ 0.4, n ϭ 12 vs. 2 Ϯ 0.4, n ϭ 8 on day 1 and 7 Ϯ 0.3, n ϭ 50 vs. 1 Ϯ 0.2, n ϭ 14 on day 3 for TNBSand sham-treated animals, respectively). The inflammation was associated with a marked decrease in body weight (5 Ϯ 0.3% of the initial body weight on day 1 and 15 Ϯ 1.6% on day 3; n ϭ 6). Importantly, contractile activity of the mesenteric collecting lymphatics draining the inflamed ileal site in the TNBS-treated animals was noticeably compromised. Specifically, the vessels were quiescent and significantly dilated, characteristics they retained after isolation even when luminally perfused at high flow rate (Fig. 4A) . A good correlation was observed between the severity of intestinal inflammation as assessed by macroscopic damage scoring and the increase in vessel diameter (Fig. 4B) .
Lymphatic muscle in vessels from TNBS-treated animal are hyperpolarized. The inability of lymphatics from inflamed animals to contract might be due to a depressed lymphatic muscle membrane potential. To test this hypothesis, we measured lymphatic muscle membrane potential in vessels from TNBS-and sham-treated guinea pigs with intracellular microelectrodes. As illustrated in Fig. 4 , C and D, the mean membrane potential value recorded in vessels from sham-treated animals (Ϫ56 Ϯ 1 mV, n ϭ 19) was not different from that measured in control animals (Ϫ52 Ϯ 1 mV, n ϭ 13). In contrast, membrane potential value recorded in vessels from TNBS-treated animals was strongly and significantly hyperpolarized (Ϫ68 Ϯ 1 mV, n ϭ 22; P Ͻ 0.05 vs. sham and control).
Inhibiting iNOS partially restores lymphatic pumping in TNBS-treated animals. To assess whether NO could be involved in the contractile dysfunction, we first examined the contractile behavior of the vessels in the presence of the selective iNOS inhibitor 1400W. A partial restoration of pumping in lymphatic vessels from TNBS-treated animals was observed after a 10-min superfusion with 10 M 1400W (Fig. 5A ).
Restoration of pumping was significant in the five vessels examined, with contraction frequency increased from 0 to 8 Ϯ 2 contractions/min during administration of 1400W (P Ͻ 0.05; Fig. 5B ), a value not significantly different form the contraction frequency observed in vessels from sham-treated animals (n ϭ 6; 10 Ϯ 1 contractions/min). However, as illustrated in Fig. 5A , the pumping behavior was not as regular as in vessels from sham-treated animals, with occasional interruptions of the contraction-relaxation cycle. Membrane potential in vessels from inflamed animals was slightly but significantly depolarized by 1400W treatment (Fig. 5C ). Neither contraction frequency nor membrane potential was affected by 1400W in vessels from sham-treated animals.
Inhibiting soluble guanylyl cyclase fully restores pumping in TNBS-treated animals. Addition of the soluble guanylyl cyclase (sGG) inhibitor ODQ (10 M) to the superfusion caused a significant and sustained reactivation of pumping in vessels from TNBS-treated animals (9 Ϯ 2 contraction/min) over the baseline period (0.4 Ϯ 0.2 contractions/min, n ϭ 6, P Ͻ 0.001; Fig. 6, A and B) . ODQ did not cause a significant change in contraction frequency in vessels isolated from sham-treated animals. Membrane potential of vessels from TNBS-treated animals was depolarized in the presence of ODQ, but not more importantly than in vessels from sham-treated animals (Fig. 6C) . Blocking K ATP channels restores pumping in dysfunctional lymphatic vessels. Opening of K ATP channels hyperpolarizes lymphatic muscle and inhibits lymphatic pumping. We thus assessed the involvement of these channels in the inflammation-induced lymphatic dysfunction and incubated the vessels with glibenclamide. Lymphatic vessels from TNBS-treated animals, showing no activity resumed contractile activity in the presence of glibenclamide (10 M) (10 Ϯ 2 contractions/min, n ϭ 12, P Ͻ 0.0001; Fig. 7, A and B) . This value was not significantly different from the contraction frequency recorded in vessels from sham-treated animals (11 Ϯ 2 contractions/ min, n ϭ 8). In the latter vessels, glibenclamide had no significant effect on contraction frequency. Administration of glibenclamide (1-10 M) also caused membrane potential of lymphatic muscle from TNBS-treated animals to depolarize (Fig. 7C) . Glibenclamide also depolarized membrane potential in vessels from sham-treated animals as already reported in control vessels (see Fig. 2F ).
Expression of iNOS mRNA increases and eNOS mRNA decreases in lymphatic vessels from TNBS-treated animals.
Relative expression of iNOS and eNOS mRNA was measured in sham-and TNBS-treated animals by real-time quantitative PCR. Analysis showed a significant increase in relative iNOS expression in the lymphatic vessels from TNBS-treated (0.4 Ϯ 0.1, n ϭ 5) vs. sham-treated animals (0.01 Ϯ 0.003, n ϭ 5, P Ͻ 0.001). Comparison of eNOS mRNA expression showed a downregulation in lymphatic vessels from TNBS-treated animals (0.3 Ϯ 0.2, n ϭ 8) compared with sham-treated animals (3.7 Ϯ 0.9, n ϭ 7, P Ͻ 0.0001; Fig. 8A) .
Expression of K ATP channel subunit mRNA increases in lymphatic vessels from TNBS-treated animals. Real-time quantitative PCR data showed that K ATP channel subunits are expressed in lymphatic vessels of sham-treated animals in roughly equal concentrations (Fig. 8B ). Our analysis revealed that expression of both channel subunits was upregulated in vessels from TNBS-treated animals, with a three-to fourfold increase in relative expression of Kir6.1 (n ϭ 5-6; P Ͻ 0.01) and SUR2B (n ϭ 5-8; P Ͻ 0.001; Fig. 8B ). Expression levels of Kir6.1 and SUR2B mRNA were comparable in TNBStreated animals.
Sensitivity to K ATP channel agonists is increased in lymphatic vessels from TNBS-treated animals.
We investigated next whether the increase in K ATP subunit mRNA expression was translated into increased sensitivity to cromakalim in lymphatics isolated from TNBS-treated animals. To cause these normally quiescent vessels to rhythmically contract and according to findings that inhibition of iNOS (current study) and COX (60) reactivate pumping, we incubated the vessels in a combination of ODQ (10 M) and indomethacin (10 M). In these conditions, vessels from TNBS-treated animals contracted at 10 Ϯ 1 contractions/min, a frequency not different from sham-treated and control vessels (Fig. 9, inset) , and were significantly more sensitive to cromakalim than vessels from sham and control animals, as illustrated by the rightward shift of the concentration-response curve (IC 50 sham-treated vessels was not significantly different from that of control vessels (IC 50 239 Ϯ 1 nM, n ϭ 4 and 315 Ϯ 1 nM, n ϭ 4, respectively, P Ͼ 0.05). We then assessed the hyperpolarizing response of inflamed vessels to cromakalim. As illustrated in Fig. 9B , the increase in sensitivity was not observed and the concentration-dependent relationship was not different from that obtained in sham or control vessels (n ϭ 3-4).
DISCUSSION
Following our previous study demonstrating that collecting mesenteric lymphatic vessels draining the guinea pig ileum were dilated and quiescent during an inflammatory episode caused by the instillation of TNBS, we reveal here the critical role played by NO in the lymphatic contractile dysfunction. Pumping inhibition was markedly reversed after treatments with the iNOS-selective inhibitor 1400W and the sGC inhibitor ODQ. Our data also revealed the pivotal involvement of K ATP channels in the lymphatic contractile dysfunction. Specifically, we showed that mRNA expression of the subunits forming K ATP channels was upregulated in collecting mesenteric lymphatic vessels draining the ileum affected by the TNBSinduced inflammation leading to an increased sensitivity to the K ATP channel activator cromakalim. Our findings that lym- phatic vessels from inflamed animals were hyperpolarized and that both membrane potential and pumping were restored following administration of the selective K ATP channel blocker, glibenclamide, also strongly support a role for K ATP channels in the inhibition of lymphatic pumping seen in TNBStreated animals. Importantly, we demonstrated that activation of the K ATP channels is strongly linked to the action of NO since NO-induced inhibition of pumping was associated with a hyperpolarization of the lymphatic muscle, both fully reversed by glibenclamide. A schematic illustration of the signaling mechanisms proposed to be involved in the inflammation-induced lymphatic contractile dysfunction is outlined in Fig. 10 .
Role of NO in inflammation-induced pumping inhibition.
Under physiological conditions, NO is constitutively produced by the lymphatic endothelium under the catalytic action of NO synthase (NOS) isoform 3 or eNOS. This enzyme has been shown by immunohistology to be substantially expressed and localized in the endothelium of collecting lymphatics (22, 32, 34) and to be particularly abundant in the valve region (4) . Pharmacological studies have consistently demonstrated that relaxation of lymphatic vessels and pumping inhibition strongly depends on NO. These studies investigated contractile responses to NO release by the lymphatic endothelium either via pharmacological stimulation (15, 32, 53, 62) or via shear forces caused by lymph flow increase during phasic contraction (20, 21, 38, 51) . The chronotropic inhibition of lymphatic contraction frequency by NO has been associated with a lymphatic muscle membrane potential hyperpolarization and a decrease in size and frequency of spontaneous transient depolarizations, electrical events shown to initiate action potentials and contractions in guinea pig mesenteric lymphatics (53, 55). Gasheva et al. (21) demonstrated that the NO pathway played a key role in the regulation of the contraction-generated reduction of lymphatic tone in the rat thoracic duct, suggesting that it was responsible for the self-regulatory adjustment of lymphatic pumping to the changes in lymph flow pattern. More recently, the role of NO was confirmed by use of genetically modified mice. Intravital microscopy was used to study contractile activity in mouse popliteal collecting lymphatic vessels and to demonstrate that pharmacological and genetic inhibition of eNOS caused a decrease in contraction strength but an increase in contraction frequency (33) .
The role played by NO in regulating lymphatic contractions may differ during inflammatory conditions, where sustained, high levels of NO are produced following upregulation of the inducible form of NO synthase (NOS-2 or iNOS) (18, 29) . In the present study, we observed that NOS expressions in guinea pig mesenteric lymphatic vessels were altered in the inflammatory setting caused by TNBS intestinal instillation, with eNOS being downregulated and iNOS upregulated. The predominant role of iNOS-produced NO in causing lymphatic contractile dysfunction was further suggested by the substantial restoration of pumping observed during inhibition of iNOS with 1400W. Although this restoration was significant in that it did cause response in otherwise completely quiescent vessels, it was usually not sustained and not recapitulating the contractile behavior observed in vessels from sham-treated animals. The more robust restoration observed during ODQ administration suggests that other sources of NO may contribute to pumping inhibition by activating guanylyl cyclase. Indeed, during intravital experiments, administration of the eNOS inhibitor N G -nitro-Larginine (100 M) to minimally active mesenteric lymphatics from TNBS-treated guinea pigs slightly improved pumping (TF Wu, unpublished data) suggesting a small involvement of eNOSderived NO in the contractile dysfunction. It is however, also possible that the inflammation present in the guinea pig ileitis model was so severe and iNOS overexpression so important that it surmounted the inhibitory ability of 1400W.
The persistence of lymphatic pumping inhibition in the in vitro experiments and the iNOS overexpression in the lymphatic isolated preparation may suggest that NO was produced in part by the vessel itself. However, possible contribution of other nonlymphatic cells present in the surrounding mesentery in producing and releasing NO or overexpressing iNOS cannot be totally excluded and the exact cellular origin of the mediator has yet to be investigated. It is even more plausible that in vivo, immune cells circulating in the lymph or around the lymphatic vessels may also participate to the release of NO and lymphatic dysfunction. Liao et al. (33) reported that the strong inhibition of lymphatic pumping observed during inflammation was mediated by NO produced by bone marrow-derived cells colonizing the vicinity of the lymphatics. Furthermore, elevated production of NO by peritoneal macrophages reported in dextran sodium sulfate (DSS) mice, another animal model of inflammatory bowel disease (1), could also contribute to impaired lymphatic function.
Interaction between NO and prostaglandin pathways. In addition to NO, other proinflammatory vasodilators are likely to be involved in the lymphatic contractile dysfunction. Indeed, 10 . Schematic illustration of the proposed mechanisms involved in inflammation-induced alteration of lymphatic contractile function. Physiological inhibition of lymphatic pumping can be achieved via endothelial release of NO, acting at least in part by the cGMP/PKG-dependent activation of KATP channels, causing a hyperpolarization of the lymphatic muscle and inhibiting action potential and Ca 2ϩ entry through voltage-dependent Ca 2ϩ channels (VDCC) and phasic contraction. During inflammation, this mechanism is amplified as a consequence of the overexpression of iNOS driving an augmented production of NO and the overexpression of the KATP channel subunits Kir6.1 and SUR2B, further strengthening the hyperpolarization of the muscle membrane potential. L-Arg, L-arginine; L-Citr, L-citrulline; sGC, soluble guanylate cyclase. improvement of pumping with indomethacin reported in the same TNBS model (60) strongly suggest a role for products of arachidonic acid metabolism. Prostacyclin and prostaglandin E 2 (PGI 2 and PGE 2 ) have been directly associated with lymphatic pumping inhibition in the same mesenteric preparation (8, 45) . Action of these mediators could further explain the incomplete effect of 1400W in restoring contractile activity in vessels from TNBS-treated animals. PGE 2 could also indirectly influence NO action, since it has been shown to downregulate iNOS at both the mRNA and protein levels (37, 50) .
As in most smooth muscle, K ATP channels can be activated via the cyclic AMP (cAMP)-protein kinase A (PKA) pathway in lymphatic muscle (52) . Cyclic nucleotides are regulated within the cell by phosphodiesterases (PDE) (17) . In the cell, cAMP levels far exceed those of cGMP; however, cGMP is able to compete for the catalytic sites of the cGMP-inhibited PDE3, therefore decreasing hydrolysis of cAMP and increasing cellular signaling via the cAMP-PKA pathway (35, 63) . This potential for cross talk between cyclic nucleotide pathways provides a possible explanation for why ODQ is so effective at restoring pumping. When soluble guanylyl cyclase is blocked by ODQ, the inhibitory effect of cGMP on PDE3 is removed, cAMP level decreases, as well as phosphorylation of K ATP channels by PKA. It is possible that the increased production of NO by iNOS contributes to a permissive effect of cGMP on the cAMP-PKA pathway. Direct phosphorylation of the K ATP channel by cGMP-dependent protein kinase G (PKG) has been reported (23) and could also account for the NOdependent activation of K ATP channel.
Role of K ATP channels in inflammation-induced pumping inhibition. Our data confirm the pivotal role played by K ATP channels in regulating lymphatic pumping (25, 30, 39, 45, 52, 58) , as evidenced by the potent action of cromakalim to hyperpolarize lymphatic muscle and abolish the phasic contractions that mesenteric lymphatics characteristically exhibit (Fig. 2) . More importantly, our findings strongly implicate K ATP channels in inhibiting contractility of the lymphatic muscle during inflammation. First, membrane potential and pumping were restored in quiescent lymphatic vessels from TNBS-treated animals following administration of the selective K ATP channel blocker glibenclamide. Second, expression of K ATP channel subunits was increased in lymphatics isolated from inflamed animals. Third, and consistently with the K ATP channel overexpression, vessels from inflamed animals were more sensitive to cromakalim than vessels from sham-treated animals. However, contractile activity in these vessels was measured under conditions in which perfusion rate was increased to 10 l/min, a value that allowed us to cause restoration of pumping in the presence of the inhibitors used. At this flow rate, sensitivity to cromakalim in control (and sham) vessels was in fact decreased compared with that in control vessels at moderate flow rate (2.5 l/min, see Fig. 2 ). Indeed, when hyperpolarizations in response to cromakalim were compared between vessels from sham-and TNBS-treated animals, a protocol in which perfusion rate was not a factor, enhanced sensitivity to cromakalim in vessels from TNBS-treated animals was not observed. It is possible that K ATP channel overexpression in vessels from TNBS-treated animals occurred to counteract the increase in transmural pressure/flow rate the vessels were exposed during intestinal inflammation and that the increased sensitivity to cromakalim could only be revealed under conditions of high flow rate mimicking the inflamed situation. Our findings bear similarities with observations by Elias et al. (14) , who described a decrease in pumping in mesenteric lymphatics of the sheep during endotoxemia and suggested that the administration of endotoxin could cause a rightward shift of the transmural pressure-fluid pumping curve, meaning that lymphatics vessels were still able to pump but that greater intraluminal pressures were required to elicit a similar level of pumping. The authors further hypothesized that a shift to the right of the transmural pressure-pumping curve would contribute to edema, because the lymphatic vessels would require accumulation of more fluid than normal to provide an increase in the transmural stimulation sufficient to activate the pump. However, such a shift in the curve to the right might be beneficial in edematous/inflammatory conditions because it could allow the lymphatic pump to be more efficient at transmural pressures that would have originally been over the peak of the pumping curve.
K ATP channels have been implicated in dysregulation of the contractile activity in several other smooth muscles during inflammatory processes, such as colonic smooth muscle activity (2, 28) during DSS-induced colitis or hypotension (19, 31) and arterial vasodilation (47) during LPS-induced inflammation and endotoxemia.
Interestingly in the context of septic shock, increase in aortic NO could be blunted by selective inhibition of iNOS (12) . This action was accompanied by a decrease in NF-B activation and a downregulation of vascular K ATP channel expression, suggesting that activation of this transcription factor by NO leads to overexpression of vascular K ATP .
Implication for resolution of edema and inflammation. During inflammation, lymphatic vessels play a dual role. While they help with edema resolution at the inflamed site, they also aid in immune cell trafficking (49) . Assuming that lymphatic pumping is critical to lymph flow regulation, high contraction frequency may increase lymph drainage and immune cells trafficking from the inflamed site to the draining lymph node, allowing an appropriate immune response to be mounted. Slowing or inhibiting pumping would then decrease immune cell trafficking and alter the immune response. Alternatively it may help to reduce a potentially exaggerated immune response. It is also possible, assuming that the increased interstitial fluid accumulated in the inflamed area produces a pressure gradient from the interstitial space to the lymphatic vessel lumen capable of maintaining a high lymph flow to the lymph nodes, that nonpumping lymphatic vessels act more efficiently as a conduit for the drainage of excess fluid and immune cells. Again, the consequence could be either an appropriate resolution of edema and immune response or promotion of an overwhelming one. To discriminate between these possibilities, efficiency of lymph flow in these inflammatory situations needs to be further examined.
